Government policies and regulations have created an environment hostile to research and innovation.
Advanced clinical trials in Canada, which were consistent between 2015 and 2019, decreased by 26 per cent in 2020.
Regardless of their potential impact on patient health, drug approval times in Canada were longer than in other countries.
Accepting FDA approvals could lead to earlier marketing availability in Canada.
Drugs were approved in the U.S. 469 days earlier (on average) than in Canada.
Planned changes would likely result in fewer new and innovative drugs available to Canadians.
Forcing manufacturers of high-cost drugs to reduce their prices by up to 80 per cent is unsustainable.